Study links influenza A viral infection to microbiome, brain gene expression changes
Peer-Reviewed Publication
Updates every hour. Last Updated: 15-Aug-2025 07:11 ET (15-Aug-2025 11:11 GMT/UTC)
A comparison of genetic data from all over the world specifies many general as well as a population-specific genetic predispositions for the neurogenerative disease Alzheimer’s. The results can lead to more precise and inclusive treatment options / publication in Nature Genetics
From the biology of aging to the future of artificial intelligence (AI)-driven medicine, Mount Sinai Health System will participate at the 2025 Aspen Ideas: Health (Sunday, June 22-Wednesday, June 25) and Aspen Ideas Festival (June 25-Tuesday, July 1) in Aspen, Colorado. Mount Sinai is proud to be a presenting underwriter of both festivals, where Mount Sinai thought leaders will lead discussions and the Health System will provide complimentary dermatologic screenings for attendees. “We return to Aspen Ideas: Health and the Aspen Ideas Festival deeply inspired—by the setting, the community, and the shared pursuit of progress,” said Brendan G. Carr, MD, MA, MS, Chief Executive Officer and the Kenneth L. Davis, MD, Distinguished Chair, Mount Sinai Health System. “This year, my colleagues will explore the emerging science of aging and inflammation and how Mount Sinai is harnessing AI to propel science and health care innovation. Our goal, as a learning health system, is to solve the world’s most complex health and science challenges to improve health of people everywhere.”
Older adults on four or more medications are one-and-a-half times more likely to experience a fall, and each additional medication increases the risk by up to 21%. This targeted approach aims to eliminate the guesswork in medication management, dramatically reducing the risk of adverse drug events—particularly dangerous falls.
Public Health researchers from UC San Diego have found that a 2016 increase in California's tobacco tax led to more people quitting.
Cambridge, MA – June 18, 2025 –Insilico Medicine(“Insilico”), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces that the first patient has been dosed in a global multicenter clinical trial (NCT06414460) to evaluate ISM3412, a potentially best-in-class, AI-empowered MAT2A inhibitor with novel structure, in patients with locally advanced and metastatic solid tumors.